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Significance Statement (119 words) 
Recent data suggest hemodialysis is capable of reducing cerebral blood flow. The 
reported propensity of dialysis related cognitive impairment to present as executive 
dysfunction has led many to assume alterations in cerebral circulation are implicated 
in cognitive decline, yet this observation has not been formally tested. This 
prospective observational study uses real time vascular imaging, brain MRI and 
neurocognitive assessments to demonstrate a correlation between dialysis related 
decrease in cerebral blood flow and tests of executive function during a single 
dialysis session and following 12 months of ongoing treatment.  MRI demonstrates 
progressive markers of small vessel disease in those on dialysis, and an increase in 
anisotropic diffusion following transplant.  These observations underpin one 
mechanism of cerebral injury in hemodialysis. 
  
Abstract  
Background:  
The immediate and longer-term effects of hemodialysis on the cerebral circulation, 
structure and function are poorly understood.  
Methods:  
Prospective observational cohort study of adults receiving chronic hemodialysis. 
Cerebral arterial mean flow velocity (MFV) throughout dialysis was assessed by 
transcranial Doppler ultrasound. Cognitive function was assessed during and out-
with dialysis and again at 12months. Brain magnetic resonance imaging (MRI) was 
performed to assess atrophy, white matter hyperintensities (WMH) and diffusion 
parameters. Correlations between MFV, cognitive scores and changes on MR were 
tested.  
Results: 
97 patients, median age [IQR] 59 [51, 67] years were recruited.  MFV declined 
during dialysis (47.38–40.75cm/s, p<0.001), correlating with ultra-filtrate volume 
(R=0.512, p<0.001).  %Decline in MFV (median [IQR] -10[-21.9, 0.0] %) correlated 
with intradialytic decline in cognitive function: namely global function (R=0.270, 
p=0.02); Trail-Making-Test (TMT) A (R=-0.454, p<0.001); TMT-B (R=-0.323, p=0. 01 
and verbal fluency (R=0.302, p=0.01). At follow-up, 73 patients were available for 
repeat testing, 34 underwent repeat MRI. 15 patients were transplanted during 
follow-up. Following 12 months of continued dialysis, n=61, %decline in MFV 
correlated with lower global and executive function (R=0.276, p=0.043 and R=-0.403, 
p=0.005) and WMH burden progressed (3.36 vs 2.96 ml, p=0.018). Following 
transplantation, memory improved (delayed recall 9.5 vs 6.5, p=0.02). Fractional 
anisotropy of white matter (0.29 vs 0.28, p=0.016) increased, correlating with 
improving executive function (R=-0.886, p=0.019). 
Conclusions:  
Hemodialysis induces transient decline in cerebral blood flow, correlating with 
intradialytic cognitive dysfunction. Progressive cerebrovascular disease occurs in 
those continuing dialysis. Improved cognitive function and cerebral diffusion is 
observed following transplantation. 
 
  
Introduction 
Cognitive impairment is highly prevalent in those on hemodialysis (HD); up to 70% in 
an unselected cohort demonstrated cognitive impairment1.  The aetiology of 
cognitive impairment in HD is multifactorial: dialysis is associated with profound 
metabolic abnormalities, chronic inflammation and oxidative and hemodynamic 
stressors. However, two important findings support the theory that cerebrovascular 
disease is the primary driving force. Specifically, dialysis preferentially induces 
deficits in executive function2–4, a pattern traditionally observed early in vascular 
cognitive impairment but only a later complication of other dementias such as 
Alzheimer’s disease5 and that more regular frequent dialysis does not improve 
cognitive function6, whereas renal transplantation can7.   
The frequency of cerebrovascular disease in people with end-stage renal disease 
(ESRD) is up to 10-fold greater8 compared to the general population and mortality 
rates approximately three-fold greater9. Although conventional stroke risk factors 
such as hypertension are ubiquitous in ESRD and partly responsible, it is likely renal 
specific factors contribute to this inordinate difference. For example, there is 
increasing evidence that both initiation10 of and exposure11,12 to HD for ESRD is 
associated with stroke, although the mechanism is not fully explained. Interestingly, 
this risk appears to be reduced by receiving a renal transplant13.  
The concept that HD can induce cerebral injury is supported by previous studies. 
Two recent prospective European studies have demonstrated evidence of decreased 
intradialytic cerebral perfusion14,15, relating this to dialysis related factors such as 
intradialytic hypotension or ultrafiltration volume. Alterations in cerebral structure are 
also described. For example, white matter hyperintensities (WMH), a marker of small 
vessel disease, are present incidentally in 11-21% of the general population aged 
around 64 years16 whereas this rises to 52% in those on HD17. Increasing WMH 
burden is associated not only with stroke18 but also cognitive impairment1.  
Real-time non-invasive measurement of cerebral blood flow is possible using 
transcranial Doppler (TCD) ultrasound, a non-invasive, inexpensive tool which is well 
tolerated and capable of performing repeated measurement throughout a dialysis 
session. Our primary hypothesis is that cerebral blood flow, measured by TCD, is 
reduced by hemodialysis and correlates with a decline in intradialytic cognitive 
function. Secondarily, we hypothesize that a reduction in cerebral blood flow is 
capable of reducing longer term cognitive function, inducing ischemic damage as 
measured by white matter hyper-intensity (WMH) burden and that progressive 
ischemia on brain MRI at 12 months will correlate with progressive cognitive decline. 
Therefore, we present a prospective investigation of real-time dialysis related 
cerebral blood flow, cognitive function on and off dialysis and brain MRI findings over 
a 12-month follow-up of continuous treatment for ESRD.  
The primary aim of this study was to explore whether HD was associated with 
changes in cerebral blood flow and determine whether these changes relate to intra-
dialytic cognitive dysfunction. Our secondary aims focus on (1) assessment of 
longitudinal changes in cerebral structure and function using brain MR imaging and 
cognitive assessment at baseline and after 12 months, correlating this to alterations 
in cerebral blood flow and (2) to compare cognitive outcomes at follow-up in those 
who remain on hemodialysis and those who receive a renal transplant.  
   
Methods  
Recruitment began in April 2015 and the first visit took place on 3 June 2015. All 
visits were completed by 7 July 2017.  Participants were asked to attend three visits 
over a 12 month follow-up period. Two visits took place within the first month:  one 
during their routine dialysis treatment (intra-dialytic assessment), and a second on a 
non-dialysis day (inter-dialytic assessment). At 12 months a repeat non-dialysis 
assessment was performed.  
Study participants 
All adult patients aged 18-85 inclusive receiving hospital hemodialysis for ESRD at 
the Glasgow Renal and Transplant unit were considered. We approached all adults 
who were expected to remain on hospital hemodialysis for ≥ 6months. Exclusion 
criteria were: inability to consent, poor comprehension of English language, a prior 
diagnosis or neuroimaging evidence of cerebrovascular disease and prior diagnoses 
of cognitive impairment. Neuroimaging evidence of cerebrovascular disease included 
all those with prior ischemic or hemorrhagic stroke in addition to those with evidence 
of small vessel disease.  Written informed consent was completed for each 
participant. This study was approved following ethical review by the West of Scotland 
research ethics committee 5, reference REC 15/WS/0024 and registered on 
ClinicalTrials.gov under identifier NCT02393222.  
Clinical Variables 
Patient demographics were acquired from the electronic patient record. Duration of 
ESRD was calculated in years from date of first RRT commencement until date of 
first visit. Pre- and post-blood pressure and ultrafiltration volumes were recorded and 
presented as an average of the last 6 readings. Laboratory values utilised the three 
latest results preceding their first visit. During the intradialytic assessment visit, blood 
pressure and weight were recorded before and after dialysis, and UF rate calculated 
as volume of fluid removed divided by duration of session.  
Dialysis Schedule 
This observational study was designed to assess the effect of dialysis in a ‘real-
world’ cohort, without intervention or interference with each participant’s routine 
treatment schedule. All participants underwent their routine prescribed dialysis 
treatment. The median [IQR] duration of dialysis was 4 [4, 4.5] hours, with median 
[IQR] blood flow rates of 300 [287.5, 305.0] mL/min. Dialysate temperature 
throughout all units is set at 36.5oC.  The first dialysis session following the ‘long gap’ 
was completely avoided. All Doppler readings were performed with patients sitting 
upright. It was essential that patients remained comfortable during their cognitive 
assessments, therefore food and rest periods were permitted.  
Cognitive Assessments 
Assessments were carried out by medical and nursing staff following training in 
appropriate use of the assessments by an experienced psychologist. At the mid-
point of our study, re-training was performed to ensure consistency of assessment. 
Intra-dialytic testing was performed within the first 2 hours of dialysis, omitting the 
first 15 minutes for initial physiological monitoring and routine nursing checks.  All 
physical assessment as part of routine dialysis was performed manually, by usual 
dialysis nursing staff. The dialysis unit staff were aware to keep interruption to a 
minimum and cognitive testing was halted during scheduled blood pressure checks. 
Where practically possible, in order to account for environmental effects on cognitive 
function participants returned to the dialysis unit for their inter-dialytic assessment.  
A modified 30-minute National Institute of Neurological Disorders and Stroke-
Canadian Stroke Network (NINDS-CSN) neuropsychological battery was used to 
assess cognitive function. This well-validated protocol was chosen due to its 
feasibility, acceptability and increased sensitivity at detecting vascular cognitive 
impairment. It consists of verbal and written assessments of multiple cognitive 
domains. Specifically, we included the Montreal Cognitive Assessment, using the 
accepted cut-off of <26 to define cognitive impairment. Verbal fluency was assessed 
using phonemic and semantic fluency, executive function using Trail-Making tests A 
& B (TMTA, TMTB) and the letter-digit substitution test (LDST) and auditory-verbal 
memory via the Hopkins Verbal Learning Test (HVLT). Finally, an assessment of 
mood was performed using the Centre for Epidemiologic Studies Depression Scale. 
Further information on each assessment is described in supplementary table s1. The 
MOCA was used to quantify ‘cognitive impairment’, therefore presented as an 
education adjusted score (addition of 1 for those with 12 year or less education). All 
other scores are presented as raw, unadjusted data. 
In an attempt to blunt possible learning effects, all visits were held a minimal 14 days 
apart. Further, we used versions 7.1, 7.2 and 7.3 of the MOCA and HVLT 1, 2, 5 and 
6 at differing visits throughout the study.  
In cases where writing was not possible, for example a participant’s inability or 
unwillingness to move their dominant arm during dialysis (n=9), the MOCA-BLIND 
method was used – adjusting the cut-off for cognitive impairment <18, and the verbal 
LDST was performed.   
Imaging 
Following training from a research neuro-sonographer, all transcranial Doppler 
ultrasound was performed by one operator (MDF). Bilateral insonation of the middle 
cerebral arteries via trans-temporal windows was attempted in all patients during 
their intra-dialytic visits using the ST3 Transcranial Doppler Spencer Technologies 
TCD (Redmond, WA, USA) with Power M-Mode 150. Measurements were 
performed with a sample of 6–9 mm and 2-MHz probes held in situ using a Marc600 
head frame. Participants were asked to wear this throughout their dialysis session. 
Power began at 100mW/cm2power and was reduced to the lowest possible setting 
for patient comfort. TCD recordings started at 50mm of depth and adjusted to 
achieve the clearest possible signal. In participants with bilateral temporal windows, 
a median value was calculated for analyses. Recording were taken approximately 15 
minutes prior to commencing dialysis, at set time intervals throughout dialysis and 
within 30 minutes of completion (figure 1).  Change in MFV was calculated as the 
reading at 30 minutes after completion minus the reading 15 minutes prior to 
commencing of dialysis.  
Brain magnetic resonance imaging (MRI) was performed in a subset of patients 
using 3-T MRI Siemens research scanners (MAGNETOM Verio or PRISMA, 
Siemens Healthcare, Erlangen, Germany); allocated randomly as the first 40 
consented to the study willing and with no contraindications to MRI. All follow-up 
imaging was performed on their original scanner to allow direct comparison.  T1, T2, 
Fluid Attenuated Inversion Recovery (FLAIR) and Diffusion Tensor Imaging (DTI) 
sequences were used to determine markers of atrophy (determined by change in 
volume of cortical grey matter, normal appearing white matter and supratentorial 
CSF volumes), white matter hyperintensity burden and cerebral diffusion, calculated 
as mean diffusivity (MD) and fractional anisotropy (FA).  
Image analyses 
MR images were analysed using volumetric analyses software. The first step in 
automated extraction of WMH volumes was to estimate the white matter area in 
each subject using atlas-based segmentation. A probability map of white matter was 
previously created from 313 volunteers aged 18-96 years19 and registered to each 
subject using non-linear (diffeomorphic) registration to provide an initial estimate of 
white matter in each subject20. Hyperintense outliers were identified on T2 FLAIR by 
transforming each voxel to a standard (z) score21. Voxels with z≥1.5 and within the 
estimated white matter area were initially defined as WMH. Final WMH estimates 
were defined by 3D Gaussian smoothing to reduce noise and account for partial 
volumes around WMH edges. Automatic WMH estimates were visually checked and 
stroke infarcts masked by a trained image analyst following STRIVE guidelines22. 
Normal-appearing tissues including cortical grey matter (GM), sub cortical GM, 
cerebral normal appearing white matter (NAWM) and supratentorial cerebrospinal 
fluid (CSF) were segmented using population specific tissue probability maps, within-
patient T1 intensity data and adjoining voxel data. Normal appearing tissue 
segmentations were checked and edited in the same manner as WMH.  
Measures of cerebral diffusion included fractional anisotropy (FA) and mean 
diffusivity (MD) that were calculated from the eigenvalues (magnitude of water 
movement in each diffusion direction) obtained with diffusion MRI. The BrainSuite 
Diffusion Pipeline (BDP)23,24 corrected geometric distortions in diffusion images and 
co-registered diffusion and structural images. FA and MD were calculated in regions 
of WMH and NAWM. 
Change in modality of renal replacement therapy  
The primary aim of our study is to observe the effect of hemodialysis treatment on 
cerebral function and structure. However, we acknowledged many patients suitable 
for recruitment may be listed for renal transplantation. Therefore, patients who 
remained on hemodialysis and those who received a renal transplant remained 
under follow-up. Death, patient request or use of peritoneal dialysis resulted in 
withdrawal from the study. A flow chart outlining recruitment, follow-up and testing is 
available in supplementary data, figure s1. 
Statistical Analyses 
Baseline demographic variables are presented as medians and compared using 
Mann-Whitney U or Chi-squared as appropriate.  
Primary Analyses  
Our primary aim was to describe alterations in cerebral blood flow and correlate this 
with intradialytic cognitive variation. Thus, mean flow velocity is presented as a 
median of MFV of all patients, demonstrating the change of MFV throughout the 
dialysis session. We applied a weighted generalised estimating equation (GEE) to 
model change in MFV, which had small amounts of missing data missing at random, 
supplementary table s2. Cognitive scores are paired data, comparing either on or off 
dialysis or again at 12 months follow-up, thus the Wilcoxon Signed Rank test is used. 
Correlation between %decline in MFV, dialysis-related variables and change in 
cognitive score were performed using Spearman’s rank correlation. Multiple 
cognitive tests were correlated against change in MFV. To account for multiple 
comparison errors we have provided both the Bonferroni and false discovery rate 
(FDR) correction, highlighting significant values within each table. Further details are 
provided in supplementary data, tables s3-4. 
Secondary Analyses 
At follow-up the cohort was divided into those remaining on hemodialysis and those 
with a renal transplant for comparison. Cognitive assessments off dialysis were 
compared at 0 and 12 months using Wilcoxon Signed Rank test and correlation with 
baseline %decline in MFV assessed using Spearman’s rank correlation. Changes in 
MR imaging findings at 0 and 12 months are also paired and so compared using 
Wilcoxon Sign Rank test and correlated with changes in cognitive assessment as 
above. Selected correlation plots are available in supplementary data, 
supplementary figures 2-5. 
Statistical analyses were performed on SPSS version 24 (IBM, Armonk, New York) 
and the GEE was implemented using the “PROC GEE” statement in the Statistical 
Analysis System (SAS) version 9.4 (© 2002-2012 SAS Institute Inc.). 
Power calculations  
To assess cognitive function we calculated 73 patients would be required to show 
that a decline in HD, based on published baseline ranges of a mean rescaled 
executive function of 8.7 (SD 2.8)3 and assuming a decline of 1 during follow up, with 
SD of mean of 3. To allow for 25% drop out, we aimed to recruit 97 patients. 
The primary analysis for the MRI study is to detect correlation between TCD and 
MRI findings as WMH lesion burden. To detect correlation r (r=0.5), using a two-
sided test at 5% significance with 80% power, the required sample size is 29. To 
allow for 25% drop out (death and renal transplant), 40 patients will be recruited.  
  
Results 
Ninety seven patients were recruited, median [IQR] age 59 [51, 67] years. 40 
(41.2%) were female and 32 (33%) diabetic. Median duration [IQR] of dialysis at first 
visit was 1.76 [0.6, 4.0] years. Eighty-eight patients completed both baseline intra- 
and inter-dialytic visits. Median [IQR] duration between baseline visits was 27 [22, 
34] days. 
Cognitive Impairment at baseline off dialysis  
Cognitive impairment was present in 43 (48.9%) of this population who were not 
known to have cognitive impairment, based on MOCA<26.  Demographics are 
demonstrated in table 1. Those with cognitive impairment were more likely to have 
evidence of systolic hypertension; pre-dialysis systolic blood pressure 148.8vs 
133.5mmHg, p=0.02. There were no differences in age or duration of ESRD. 
Hemodialysis and Cerebral Blood Flow 
Insonation of ≥1 middle cerebral artery was possible in 82 participants, being not-
visible or deemed unreliable in the remainder. 18 of 82 were unable to continuously 
wear the headset throughout dialysis: in 8 participants the headset was ill-fitting or 
uncomfortable and a further 10 participants requested removal within the first 2 
hours, with 6 complaining of a headache, relieved immediately on removal.  Mean 
flow velocity (MFV) declined following dialysis remaining lower up to 30 minutes after 
completion of dialysis, median MFV reading 47.38 to 40.75 cm/s, p<0.001, figure 1. 
The median [IQR] %decline was -10[-21.9, 0.0] %. The %decline in MFV correlated 
with UF volume and rate and change in weight, rho 0.512, 0.493 and 0.463 
respectively, p<0.001 but not change in absolute blood pressure values. Change in 
mean arterial pressure and presence of diabetes weakly correlated with a %decline 
in MFV, table 2.  
Cognitive Function: on and off dialysis assessments 
Compared to their assessments during an off-dialysis period, participants scored 
lower in assessments of executive function during dialysis; processing speed 
(LDST), 22 vs 24.5, p<0.001 and attention/task switching (TMTB), time-taken 88.5 vs 
75 sec, p<0.001, table 3.  
Significant correlations between the %decline in MFV during dialysis and a decline in 
TMTA, rho -0.454, p<0.001, TMTB, rho -0.323, p=0.01 and phonemic fluency, rho 
0.302, p=0.01 during dialysis were detected. Further, worsening scores on global 
cognitive assessment (MOCA) during dialysis correlated with %decline in MFV (rho 
0.270, p=0.02), table 3.   
Follow-up 
Median [IQR] follow-up was 1.05 [1.0, 1.1] years.  At follow-up, 15 participants had 
been transplanted, 4 withdrew and 6 died (supplementary data, figure s1). Those 
who were transplanted were younger, median [IQR] 51 [40, 63] vs 60 [52, 67] years 
and had a shorter duration of ESRD, median [IQR] 0.6 [0.2, 1.6] vs 2.1 [0.7, 4.5] 
years, supplementary table s5. Paired 0 and 12 month inter-dialytic assessments 
were possible in 61 of those who remained on HD and 12 who received a kidney 
transplant. Baseline and follow-up MRI data were available in 24 who continued HD 
and 10 who were transplanted.  
Cognitive function at follow-up: continued hemodialysis vs transplanted 
At 12 months follow-up those who remained on dialysis had an improvement in 
MOCA score, 26 vs 24, p<0.01. No other assessment revealed significant 
differences. In contrast, those who underwent transplant had no change in their 
MOCA score, 26 vs 26, p=0.23, but demonstrated an improvement in verbal 
memory: delayed recall, 9.5 vs 6.5, p=0.02; retention, 100 vs 68.3%, p=0.03 and 
discrimination, 11 vs 10, p=0.03, table 4.  
In those who remain on dialysis %decline in MFV was significantly correlated with 
worsening score in global cognitive function (MOCA) and executive function (TMTB) 
on follow-up, rho 0.276 p=0.043 and rho -0.403, p=0.005 respectively, table 4.  
In those who received a transplant an observed %decline in MFV correlated with 
worsening phonemic fluency at follow-up, rho 0.758. p=0.011, table 4. 
MR derived structural Changes 
In those who continued on dialysis, progressive lobar atrophy was evident in frontal, 
parietal and temporal lobes, p<0.05, table 5. White matter hyperintensity burden 
increased, 2.96-3.36mL, p=0.018, figure 2. There were no changes in DTI measures, 
FA and MD, table 5.  
Following kidney transplant, a similar pattern of lobar atrophy was noted. However, 
there was no progression in WMH burden. Fractional anisotropy in white matter 
increased, 0.28 - 0.29, p=0.016, table 5. 
Correlating structural changes with cognitive function 
There was no correlation between %decline in MFV assessed at baseline and MRI 
findings.  
In those who continue dialysis greater frontal atrophy correlates with worsening 
score in global cognitive and executive function, MOCA, rho 0.454, p=0.04, TMTB –
rho 0.620, p=0.01 and auditory-verbal memory, rho 0.805, p=0.01. An increase in 
WMH burden correlates with verbal fluency and mood, rho 0.585, p=0.01 and rho -
0.485, p=0.03, table 6. 
In who received a kidney transplant, an increase in WMH burden correlates with 
worsening executive function, TMTB rho -0.81, p=0.015. In contrast, an increase in 
fractional anisotropy correlates with an improvement in executive function, LDST rho 
-0.886, p=0.019.  Surprisingly, worsening frontal atrophy correlated with 
improvement in executive function.  
Discussion 
This prospective study of people with ESRD encompassing blood flow, functional 
and structural assessments of the brain has several important findings. Firstly, we 
demonstrated that cerebral blood flow declines during dialysis, correlating with 
ultrafiltration volumes and with a measurable decline in executive function. At follow-
up, a correlation was detected between reduced cerebral blood flow and executive 
function in those who remained on dialysis but not those who were transplanted. 
Following transplant, verbal learning and memory improved. Finally, brain MRI 
revealed progressive WMH burden in those who remain on dialysis, but not those 
were transplanted. In contrast, after transplantation increased fractional anisotropy of 
the white matter correlated with improved executive function.  
We believe this study supports the hypothesis that hemodialysis may be associated 
with short-term ‘cerebral-stunning’ and demonstrates progressive injury in those who 
remain on dialysis, whereas there is a demonstrable improvement in memory and 
white matter integrity in those who are transplanted.  Early recognition of those at 
risk may limit this cerebral injury, which appears potentially reversible by 
transplantation.  
Cognitive function in ESRD: incidence and consequences 
We have demonstrated in a ‘low-risk’ HD population, without recorded 
cerebrovascular disease or cognitive impairment, that mild cognitive impairment is 
present in 48.9%. Once end-stage renal disease is established, it is estimated that 
up to 70% of those on HD have cognitive impairment 1. Surprisingly, in that particular 
study only ~3% had documentation of cognitive impairment. We demonstrated 
intradialytic cerebral blood flow declines with increasing ultrafiltration volumes 
Therefore, in ESRD, failure to recognise cognitive impairment could perpetuate 
future cognitive decline; due to cognitive impairment patient concordance with fluid 
restriction is poor , a necessary increase in ultrafiltration volumes compromise 
cerebral circulation cognition worsens and concordance worsens still.  . Morbidity 
aside, cognitive dysfunction is also associated with all-cause mortality25,26 and 
dialysis withdrawal27. 
Dialysis and Cognitive Dysfunction  
Multiple factors are reported to influence cognitive function in CKD.  Conventional 
risk factors such as age, diabetes, hypertension and dyslipidaemia are abundant 
however unconventional ‘renal’ factors including treatments for CKD e.g. the 
historical effect of aluminium toxicity28 or more recently the effect of dialysis itself  are 
implicated2,29–31.  In contrast to neurodegenerative cognitive disorders where 
memory is predominantly affected, the pattern of cognitive impairment most 
commonly described in those with CKD is loss of executive function2–4, a phenotype 
associated with vascular cognitive impairment. Further, more intensive dialysis does 
not improve function6,7. This has led to the conclusion that cognitive impairment is 
driven by cerebrovascular disease.  
Previous data on cognitive variation around the dialysis session are conflicting. 
Authors have described both improvements31,32 and worsening30 of post dialysis 
cognition. We believe we are the first study to correlate an acute change in cerebral 
blood flow with real-time alterations in cognitive function.  This has several important 
implications. Immediately, clinicians should be aware that detailed clinical 
discussions should not be undertaken during hemodialysis as comprehension and 
recall maybe affected. Further, this must prompt additional research designed to limit 
the damage observed on MRI. One clinical trial has demonstrated using dialysate 
cooling can provides stability in white matter integrity at one year33. The beneficial 
cognitive effects of renal transplantation require further attention and the benefit of 
expediting transplantation as a treatment for early cognitive dysfunction should not 
be overlooked.  
Transplantation and Cognitive Dysfunction 
Renal transplantation remains the ‘gold standard’ treatment for ESRD34 . 
Transplantation reduces the risk of cardiovascular disease35, increasing life 
expectancy and improves quality of life36. In our study we have observed, as others 
have37–39, an improvement in cognitive function following transplantation, specifically 
memory albeit in a small cohort of our patients. Fractional anisotropy is a marker of 
white matter integrity and deficits in diffusion are recognised to precede white matter 
hyper intensity formation and are associated with worsening executive function40. In 
those who received a renal transplant, FA improved and correlated with improved 
executive function, whereas there was no demonstrable improvement in anisotropic 
diffusion in those remaining on hemodialysis. Previous authors have demonstrated 
improvement in executive function following transplantation38, a finding that does not 
appear to achievable by more frequent dialysis. In an analysis of participants in the 
Frequent Hemodialysis Network  an improvement in auditory-verbal memory and 
processing speed was observed following transplantation, but not after 12 months of 
frequent hemodialysis (6 days/week)7. This is supportive of a ‘side-effect’ produced 
by HD, ameliorated by transplantation.  
Limitations 
This prospective observational cohort study has demonstrated important findings in a 
real-world ESRD cohort. However, we recognise the following limitations. As an 
observational study we cannot prove causation due to inability to account for 
unmeasured variables. For example, we do not have bicarbonate or blood viscosity 
levels which may be of greater significance than ultrafiltration volume on MFV. We 
excluded those with any known evidence of cerebrovascular disease which resulted 
in a younger cohort. This reduces generalisability and makes it likely we have 
underestimated the prevalence of cognitive impairment and the impact of ongoing 
treatments on more ‘fragile’ brains. Whilst we acknowledge this as a limitation, we 
also believe this makes our findings all the more striking. No attempts were made to 
standardise dialysis regimes. Although this could mask findings acutely, we believe 
this provides a more realistic view of dialysis. Use of transcranial Doppler ultrasound 
to measure cerebral blood flow has limitations, namely operator variability and 
absence of acoustic windows. All TCD readings were performed by one trained 
operator to reduce variation and we acknowledge TCD was not possible in 15 (15%) 
of our recruited cohort. Our findings are correlated to MFV changes over a single 
dialysis session, with follow-up spanning an entire year. Generalising one session to 
an entire year may impact on correlations at follow-up. As TCD measurements were 
taken at fixed time points it not possible to comment on unrecorded episodes of 
acute decline in MFV. Finally, throughout this manuscript we refer to cerebral blood 
flow. It is important to clarify transcranial Doppler measures cerebral blood flow 
velocity, an indirect measure of cerebral blood flow providing the diameter of the 
insonated vessel does not change during measurements. It is not known whether 
hemodialysis alters cerebral vessel diameter.   
Attempts were made to limit a learning effect. Namely, multiple versions of MOCA 
and HVLT were used, a minimum of 14 days between assessments was allowed and 
visit order was reversed in a randomly selected 20%. Despite our attempts we 
cannot completely exclude this learning effect. Frontal atrophy correlated with 
improved executive function in transplanted patients. Whilst frontal atrophy is a 
marker of aging, and executive function can improve following transplantation38 it is 
important to acknowledge our low number of transplant patients at follow-up, which 
could introduce both type 1 and 2 errors. In particular – this small number may lead 
to chance association between MR imaging findings and change in cognitive 
function. We did not detect correlation between MFV and MRI changes. Only 24 
patients completed follow-up scans in 24 patients whilst on continued dialysis. 
Therefore, correlating %decline MFV with MRI findings is underpowered and may 
account for the lack of effect. Finally, and with particular reference to the young age 
of our cohort, we did not detect progressive cognitive dysfunction – rather 
improvement in MOCA score at 12 months in those on continued dialysis. It is likely 
that the follow-up time was too short to detect a measurable difference in cognitive 
function in this recruited cohort.  
Conclusions 
Our study has highlighted the high frequency of occult cognitive impairment, 
affecting 50% of our prevalent dialysis cohort without known cerebrovascular 
disease. Hemodialysis is capable of inducing a transient decline in cerebral blood 
flow, correlating with intradialytic cognitive dysfunction. Evidence of progressive 
cerebrovascular disease is demonstrated in those who remain on dialysis, whereas 
following transplantation improvement in cognitive function and cerebral anisotropic 
diffusion is suggestive of reversibility. Urgent interventions are required to limit 
cerebral stunning and prevent progressive cognitive decline.  
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 Table 1 Demographics of study cohort, split by presence or absence of mild cognitive impairment using MOCA 
score <26 on baseline non-dialysis day assessment, n=88. Abbreviations: ESRD, end-stage renal disease; IQR, 
interquartile range; SBP, systolic blood pressure; DBP, diastolic blood pressure; UF, ultrafiltration; AV, 
arteriovenous; PTH, parathyroid hormone.  
 No Cognitive 
Impairment 
Cognitive 
Impairment 
ALL p-
value 
Median age, years [IQR] 58 [49,66] 58 [51,67] 58 [50.5,66.5] 0.61 
Female, n [%] 20 [44.4] 15 [34.9] 35 [39.8] 0.36 
Active on Transplant Waiting list. n [%] 20 [44.4] 17 [39.5] 37 [38.6] 0.64 
Ethnicity. n [%] 
       European 
       Asian 
 
43 [95.6] 
2 [4.4] 
 
41 [95.3] 
2 [4.7] 
 
84 [95.5] 
4 [4.5] 
 
 
0.96 
Primary Renal Diagnosis. n [%] 
       Diabetes 
       Glomerulonephritis 
       Interstitial 
       Multisystem 
       Other 
 
8 [17.8] 
8 [17.8] 
11 [24.4] 
7 [15.6] 
11 [24.4] 
 
10 [23.3] 
11 [25.6] 
5 [11.6] 
10 [23.3] 
7 [16.3] 
 
18 [20.5] 
19 [21.6] 
16 [18.2] 
17 [19.3] 
18 [20.5] 
 
 
 
 
 
0.36 
Past Medical History. n [%] 
       Hypertension 
       Diabetes mellitus 
       Ischemic heart disease 
       Congestive cardiac failure 
       Peripheral Vascular disease 
       Atrial Fibrillation 
       Depression 
 
37 [82.2] 
14 [31.1] 
11 [24.4] 
3 [6.7] 
3 [6.7] 
5 [11.1] 
8 [17.8] 
 
41 [95.2] 
15 [34.9] 
8 [18.6] 
6 [14.0] 
3 [7.0] 
4 [9.3] 
10 [23.3] 
 
78 [88.6] 
29 [33.0] 
19 [21.6] 
9 [10.2] 
6 [6.8] 
9 [10.2] 
18 [20.5] 
 
0.05 
0.71 
0.51 
0.26 
0.95 
0.78 
0.52 
Duration of ESRD, years [IQR] 1.39 [0.61,3.34] 1.92 [0.52,4.39] 1.62 [0.57,4.02] 0.84 
Dialysis Related Variables, median [IQR] 
       Pre-SBP, mmHg 
       Pre-DBP, mmHg 
       Post-SBP, mmHg 
       Post-DBP, mmHg 
       UF Volume, L 
       UF Rate, mL/hour 
 
133.5 [120.8,153.3] 
70.8 [65.2,81.7] 
122.7 [112.4,143.8] 
68.0 [59.5,80.2] 
2.0 [1.3,2.4] 
-442.1 [-240.0,-575.0] 
 
148.8 [129.3,168.0] 
74.8 [65.0,79.8] 
135.7 [118.2,158.0] 
71.2 [61.0,77.7] 
2.1 [1.4.2.9] 
-500.0 [-350,-622.2] 
 
143.5 [121.4,158.5] 
73.1 [65.1,80.7] 
130.7 [113.4,148.5] 
69.3 [60.1,78.2] 
2.1 [1.4,2.6] 
-484.4 [-261.9,-
484.4] 
 
0.02 
0.61 
0.03 
0.59 
0.13 
0.32 
Dialysis Access. n [%] 
       AV access 
       Central Venous Catheter  
 
34 [75.6] 
11 [24.4] 
 
28 [65.1] 
15 [34.9] 
 
62 [70.5] 
26 [29.5] 
 
 
0.28 
Median Laboratory Values [IQR] 
       Serum Adjusted Calcium, mmol/L 
       Serum Phosphate, mmol/L 
       Hemoglobin, g/L 
       Serum Albumin, mmol/L 
       PTH, nmol/L 
       Urea Reduction Ratio 
 
2.39 [2.29,2.46] 
1.76 [1.42,2.03] 
117.7 [106.7,122.7] 
33.0 [31.7,35.3] 
68.6 [42.6,98.2] 
71.5 [69,77] 
 
2.37 [2.27,2.45] 
1.74 [1.49,2.04] 
110.7 
[101.0,120.33] 
33.3 [29.7,34.3] 
53.3 [32.3,103.5] 
73.5 [70.0,76.0] 
 
2.38 [2.28,2.46] 
1.75 [1.47,2.04] 
113 [102.2,122.0 
33.2 [30.8,35.0] 
61.6 [37.4,99.0] 
72.8 [69.5,77.0] 
 
0.59 
0.90 
0.13 
0.94 
0.31 
0.58 
Median Years of Education [IQR} 12 [11.0,13.5] 12 [11.0,14.0] 12 [11,14] 0.71 
  
Figure 1 Change in mean flow velocity during diaysis session, n=82, described as median value and 
interquartile range (error bars). Transcranial doppler recordings were taken prior, during and after completion 
of dialysis, demonstrating a significant decline in MFV following dialysis, weighted generalised estimating 
equation p<0.0001. Abbreviations: MFV, mean flow velocity.  
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Variable Spearmann’s Rho p-value 
       Ultrafiltration volume, mL 0.512 <0.001 
       Ultrafiltration rate, mL/hr 0.493 <0.001 
       Delta SBP, mmHg (pre-post) 0.196 0.08 
       Delta DBP, mmHg (pre-post) 0.163 0.14 
       Delta Weight, kg (pre-post) 0.463 <0.001 
       Delta MAP, (pre-post) 
       Diabetes mellitus 
0.219 
-0.304 
0.048 
0.005 
 
Table 2 Clinical variables and their correlation to %decline in middle cerebral artery mean flow velocity, n=82. 
Delta values are calculated as pre minus post values, therefore the greater the fall after dialysis the higher the 
value.  A positive correlation denotes as % decline becomes more positive (i.e. a greater decline in MFV) the 
associated variable becomes more positive.  Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood 
pressure.  
 
 
Assessment, n=88 Intradialytic 
Assessment 
 
Interdialytic 
Assessment 
p-value Correlation with 
% decline MFV, 
Rho 
p-value 
Global Cognitive Function      
       MOCA 25.0 [22.0,27.0] 25.0 [21.5,27.0] 0.44 0.270 0.022 
Verbal Fluency 
       Semantic 18.0 [14.5,21.5] 18.0 [15.0,22.0] 0.28 0.172 0.14 
       Phonemic 33 [26.0,41.5] 34.0 [25.0,43.5] 0.49 0.302 0.012 
Executive Function      
       TMTA 38.0 [26.5,51.0] 35.5 [26.9,50.0] 0.63 -0.454 <0.0011, 2  
       TMTB 88.5 [62.0,136.0] 75.0 [54.0,112.0] <0.001 -0.323 0.012 
       LDST 22.0 [18.0,27.0] 24.5 [20.0,30.0] <0.001 -0.170 0.15 
Auditory-Verbal Memory      
       HVLT 
              Total Recall 
              Delayed Recall 
              Retention 
              Discrimination 
 
22.0 [19.5,25.5] 
7.0 [5.0,9.0] 
80.0 [60.0,90.0] 
10.0 [9.0,11.0] 
 
20.0 [17.0,23.0] 
6.0 [4.0,9.0] 
80.0 [60.0,100.0] 
10.0 [9.0,11.0] 
 
<0.001 
0.13 
0.60 
0.90 
 
0.089 
0.098 
-0.046 
0.057 
 
0.45 
0.41 
0.70 
0.63 
Mood      
       CES-D 8.0 [4.0,17.0] 9.0 [4.0,17.5] 0.80 0.097 0.41 
 
Table 3 Differences in cognitive scores during and outwith dialysis, n=88, and correlation between %decline in 
MFV and cognitive scores. Difference in cognitive score is calculated as non-dialysis score minus dialysis score.  
Positive rho = as %decline increases (i.e. a greater fall in MFV) the difference in cognitive scores becomes more 
positive. In the above tests a positive difference in cognitive score describes a lower cognitive score during 
dialysis, with the exception of TMTA, TMTB and CES-D where the inverse is true. Correlations which remain 
significant following Bonferroni correction are marked with superscript 1, and FDR 2. Abbreviations: MOCA, 
Montreal Cognitive Assessment; LDST, letter-digit substitution test; TMTA, Trail Making Test A; TMTB, Trail 
Making Test B; HVLT, Hopkins Verbal Learning Test; CES-D, Centre for Epidemiologic Studies Depression Scale; 
FDR, false detection rate.   
 
  
 Assessment Baseline 
Assessment  
Follow-up 
Assessment 
p-
value 
Correlation 
with 
%declineMFV, 
Rho 
p-value 
Continued Hemodialysis, n=61                                                          
MOCA 24.0 [21.0,27.0] 26.0 [23.0,28.0] <0.01 0.276 0.043 
Semantic 19.0 [15.0,21.0] 18.0 [15.0,21.0] 0.45 0.201 0.15 
Phonemic 35.0 [28.0,44.0] 37.0 [27.0,46.0] 0.06 0.150 0.28 
LDST 24.0 [20.0,31.0] 26.0 [20.0,31.0] 0.87 -0.085 0.55 
TMTA 34.0 [26.0,47.0] 31.0 [26.0,45.0] 0.09 -0.209 0.15 
TMTB 71.0 [49.0,99.0] 66.0 [49.0,99.0] 0.90 -0.403 0.0052 
HVLT 
       Total Recall 
       Delayed Recall 
       Retention 
       Discrimination 
 
20.0 [17.0,23.0] 
7.0 [4.0,10.0] 
80.0 [62.5,100.0] 
11.0 [9.0,12.0] 
 
21.0 [17.0,26.0] 
7.0 [4.0,9.0] 
80.0 [55.6,90.9] 
11.0 [9.0,12.0] 
 
0.28 
0.97 
0.45 
0.92 
 
0.098 
0.243 
0.219 
0.149 
 
0.48 
0.08 
0.15 
0.30 
CES-D 10.0 [5.0,18.0] 10.0 [4.0,18.0] 0.59 0.139 0.32 
Transplanted at follow-up, n=12                                                                                                                                                              
MOCA 26.0 [24.5,27.0] 26.0 [25.0,28.5] 0.23 0.086 0.81 
Semantic 18.0 [15.5,26.0] 21.0 [20.5,23.5] 0.42 0.609 0.06 
Phonemic 33.5 [28.5,46.0] 36.0 [28.5,42.0] 0.96 0.758 0.011 
LDST 31.0 [26.0,35.0] 33.0 [26.0,35.0] 0.43 0.383 0.28 
TMTA 35.0 [26.0,37.0] 34.5 [20.5,41.0] 0.63 -0.500 0.17 
TMTB 63.0 [51.0,108.0] 58.0 [45.0,82.0] 0.33 -0.317 0.41 
HVLT 
       Total Recall 
       Delayed Recall 
       Retention 
       Discrimination 
 
21.0 [17.5,24.0] 
6.5 [4.5,8.0] 
68.3 [59.8,94.4] 
10.0 [10.0,11.0] 
 
22.5 [19.5,27.5] 
9.5 [7.0,10.0] 
100.0 
[79.8,105.0] 
11.0 [10.5,12.0] 
 
0.35 
0.02 
0.03 
0.03 
 
0.329 
-0.123 
-0.358 
0.273 
 
0.35 
0.74 
0.31 
0.45 
CES-D 6.5 [1.0,13.0] 2.5 [1.0,8.0] 0.31 -0.334 0.35 
 
Table 4 Differences in cognitive scores at baseline and follow-up (using interdialytic assessments) and 
correlation between %decline in MFV and cognitive scores in those remaining on hemodialysis and those 
receiving a kidney transplant. Difference in cognitive score is calculated as baseline minus follow-up score.  
Therefore, positive rho value = as %decline increases (i.e. a greater fall in MFV) difference in cognitive change 
becomes more positive. In the above tests a positive difference in cognitive score denotes deterioration at 
follow-up, with the exception of TMTA, TMTB and CES-D where the inverse is true. Correlations which remain 
significant following Bonferroni correction are marked with superscript 1, and FDR 2. Abbreviations: MOCA, 
Montreal Cognitive  Assessment; LDST, letter-digit substitution test; TMTA, Trail Making Test A; TMTB, Trail 
Making Test B; HVLT, Hopkins Verbal Learning Test; CES-D, Centre for Epidemiologic Studies Depression Scale; 
FDR, false detection rate. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Progression of periventricular white matter hyperintesities (WMH) over 12 months in a patient on 
continued hemodialysis, baseline images on left, follow-up on right.Additionally, a loss of cerebral volume can 
be appreciated as enlargement of lateral ventricles. Figure demontrates visible progression of WMH on 
standard T2 FLAIR sequences (top row) and after application of volumetric analyses software (bottom row).  
 
  
Assessment Baseline Assesment  Follow-up Assesment p-value 
Continued Hemodialysis, n=24 
Median Lobar Vol. (mL)    
       Frontal GM 160.3 [150.8,166.3] 155.2 [147.4,162.3] 0.015 
       Parietal GM 93.9 [89.1,102.6] 92.9 [85.4,99.2] 0.028 
       Temporal GM 116.8 [110.5,122.8] 111.3 [105.6,121.6] 0.009 
       Occipital GM 60.4 [55.2,65.9] 58.3 [54.8,63.6] 0.08 
WMH Volume, mL 2.96 [0.87,6.07] 3.36 [0.82,7.35] 0.018 
DTI    
       FA_WM 0.27 [0.02] 0.26 [0.02] 0.41 
       FA_WMH 0.26 [0.04] 0.26 [0.03] 0.64 
       MD_WM 103m2/s 0.9 [0.1] 0.9 [0.1] 0.19 
       MD_WMH 103m2/s 1.2 [0.01] 1.2 [0.1] 0.05 
Transplanted at follow-up, n=10 
Median Lobar Vol. (mL)    
       Frontal GM 166.9 [159.9,185.0] 162.2 [157.4,186.4] 0.028 
       Parietal GM 102.6 [98.1,114.8] 101.6 [97.8,112.2] 0.047 
       Temporal GM 115.0 [111.6,136.6] 113.8 [108,134.5] 0.009 
       Occipital GM 64.2 [60.1,75.6] 64.8 [59.7,73.9] 0.33 
WMH Volume, mL 1.02[0.79,2.01] 1.17 [0.64,1.25] 0.24 
DTI    
       FA_WM 0.28 [0.01] 0.29 [0.01] 0.016 
       FA_WMH 0.25 [0.03] 0.26 [0.03] 0.07 
       MD_WM 103m2/s 0.8 [0.01] 0.8 [0.02] 0.62 
       MD_WMH 103m2/s 1.1 [0.1] 1.1 [0.1] 0.72 
 
Table 5 Differences in neuroimaging parameters at baseline and follow-up in those who remain on dialysis and 
those who received a kidney transplant. Abbreviations: GM, Grey Matter; WMH, White matter 
hyperintensities; DTI, Diffusion Tensor Imaging; FA_WM, Fractional Anisotropy in white matter;  FA_WMH, 
Fractional Anisotropy in white matter hyperintesities; MD_WM, Mean diffusivity in white matter; MD_WMH, 
Mean diffusivity in white matter hyperintensities 
  
Assessment Correlation with 
ΔWMH 
p-value Correlation with 
ΔFA_WM 
p-value 
Continued Hemodialysis, n=21 
MOCA 0.172 0.46 0.225 0.48 
Semantic -0.028 0.90 -0.175 0.59 
Phonemic 0.585 0.01 -0.365 0.24 
LDST 0.129 0.58 0.116 0.72 
TMTA 0.328 0.16 -0.278 0.41 
TMTB -0.384 0.12 -0.103 0.78 
HVLT 
       Total Recall 
       Delayed Recall 
       Retention 
       Discrimination 
 
0.271 
0.268 
0.172 
0.296 
 
0.23 
0.24 
0.46 
0.19 
 
0.327 
0.160 
0.056 
-0.381 
 
0.30 
0.62 
0.86 
0.22 
CES-D -0.485 0.03* 0.140 0.66 
Transplanted at follow-up, n=9 
MOCA -0.092 0.81 0.319 0.54 
Semantic -0.301 0.43 -0.600 0.21 
Phonemic 0.460 0.21 -0.667 0.15 
LDST -0.101 0.80 -0.886 0.019 
TMTA 0.071 0.87 0.200 0.75 
TMTB -0.810 0.015 -0.600 0.29 
HVLT 
       Total Recall 
       Delayed Recall 
       Retention 
       Discrimination 
 
0.025 
0.522 
0.483 
-0.173 
 
0.95 
0.15 
0.19 
0.65 
 
-0.232 
0.353 
-0.143 
0.152 
 
0.66 
0.49 
0.79 
0.77 
CES-D 0.460 0.21 -0.143 0.79 
 
Table 6 Correlations of changes in neuroimaging with change in cognitive testing over 12 months, in those who remain on 
hemodialysis and those receiving a kidney transplant.  For all neuroimaging results, values are = follow-up minus baseline, hence 
a reduction in value with time will produce a negative result. As previous, difference in cognitive score is calculated as baseline 
minus follow-up score. Therefore, positive rho = positive neuroimaging change relates to a positive cognitive score at follow-up. 
In the above tests a positive follow-up cognitive score denotes deterioration, with the exception of TMTA, TMTB and CES-D 
where the inverse is true. Abbreviations: WMH, White matter hyperintesities; FA_WM, Fractional anisotropy in white matter; 
MOCA, Montreal Cognitive Assessment; LDST, letter-digit substitution test; TMTA, Trail Making Test A; TMTB, Trail Making Test 
B; HVLT, Hopkins Verbal Learning Test; CES-D, Centre for Epidemiologic Studies Depression Scale  
 
 
 
